Patent CA-3093036-A1 (CA)
Title: Anti-pd-1 antibody compositions
Inventor: AHMED SYED SALEEM
IPC: A61K39/395
Filed: 2019-03-04
Abstract: (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY  (PCT) (19) World Intellectual Property             111111 1011E1 1111110111 Organization International Bureau (10) International Publication Number (43) International Publication Date                WO 2019/171253 Al 12 September 2019 (12.09.2019) WIPO I PCT (51) International Patent Classification: A61K 9/00 (2006.01)     A61K 47/26 (2006.01) Declarations under Rule 4.17: A61K 39/395 (2006.01)    A61K 9/08 (2006.01) ¨    as to apphcant's entitlement to apply for and be granted a patent (Ruk 4.170) A61K 47/18 (2017.01) ¨    as to the applicant's entitlement to claim the priority of the (21) International Application Number:    earlier application (Rule 4.17(iii)) Published: (22) International Filing Date:    ¨ with international search report (Art.  21(3)) 04 March 2019 (04.03.2019) ¨ before the expiration of the time limit for amending the claims and to he republished in the event of receipt of (25) Filing Language:                   English amendments (Rule 48.2(h)) (26) Publication Language:                                                  English ¨ with sequence listing part of description (Rule 5.2(a)) (30) Priority Data: 62/639,587        07 March 2018 (07.03.2018)    US 62/807,912                              20 Febmary 2019 (20.02.2019) US (71) Applicant: PFIZER INC. [US/US], 235 East 42nd Street, New York, NY 10017 (US). (72) Inventors: AIIMED, Syed Saleem; 15527 Surnmer Ridge Drive, Chesterfield, MO 63017 (US). BALTHAZOR, Bryan Mark; 804 Tavalon Avenue, Rock Hill, MO 63 119 ¨      (US). MEIITA, Anjali Pramod; 16561 Branchwood Dri-ve, Wildwood, MO 63011 (US). QURESH1, Tiharni; 2920 Texas Avenue, St. Louis, MO 63118 (US). ¨ (74) Agent: ZIELINSKI, Bryan C.; Pfizer Inc., 235 East 42nd Street, MS 235/9/S20, New York, NY 10017 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL. IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. ______________________________________  (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SL SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, 44     KM, ML, MR, NE, SN, TD, TG). kr; (-4 cN (54) Title: ANTI-PD-1 ANTIBODY COMPOSITIONS 0    (57) Abstract: The present invention relates generally to the field o f pharmaceutical formulations of antibodies. Specifically, the present es1 invention relates to a high concentration antibody formulation and its pharmaceutical preparation and use. This invention is exemplified C by a formulation of an anti-PD-1 antibody. Date Recue/Date Received 2020-09-02